|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TNKS2 |
Gene summary for TNKS2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TNKS2 | Gene ID | 80351 |
| Gene name | tankyrase 2 | |
| Gene Alias | ARTD6 | |
| Cytomap | 10q23.32 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q9H2K2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80351 | TNKS2 | LZE4T | Human | Esophagus | ESCC | 7.79e-04 | 8.95e-02 | 0.0811 |
| 80351 | TNKS2 | LZE5T | Human | Esophagus | ESCC | 2.26e-02 | 3.90e-01 | 0.0514 |
| 80351 | TNKS2 | LZE8T | Human | Esophagus | ESCC | 3.71e-05 | 2.89e-02 | 0.067 |
| 80351 | TNKS2 | LZE20T | Human | Esophagus | ESCC | 6.19e-05 | 1.10e-01 | 0.0662 |
| 80351 | TNKS2 | LZE22D1 | Human | Esophagus | HGIN | 4.58e-03 | 2.90e-02 | 0.0595 |
| 80351 | TNKS2 | LZE22T | Human | Esophagus | ESCC | 1.05e-02 | 2.17e-01 | 0.068 |
| 80351 | TNKS2 | LZE24T | Human | Esophagus | ESCC | 3.18e-26 | 7.01e-01 | 0.0596 |
| 80351 | TNKS2 | LZE21T | Human | Esophagus | ESCC | 3.60e-04 | 2.78e-01 | 0.0655 |
| 80351 | TNKS2 | P1T-E | Human | Esophagus | ESCC | 1.52e-12 | 6.29e-01 | 0.0875 |
| 80351 | TNKS2 | P2T-E | Human | Esophagus | ESCC | 1.10e-23 | 5.34e-01 | 0.1177 |
| 80351 | TNKS2 | P4T-E | Human | Esophagus | ESCC | 7.35e-21 | 4.87e-01 | 0.1323 |
| 80351 | TNKS2 | P5T-E | Human | Esophagus | ESCC | 3.17e-17 | 1.85e-01 | 0.1327 |
| 80351 | TNKS2 | P8T-E | Human | Esophagus | ESCC | 1.29e-20 | 4.07e-01 | 0.0889 |
| 80351 | TNKS2 | P9T-E | Human | Esophagus | ESCC | 4.02e-08 | 9.39e-02 | 0.1131 |
| 80351 | TNKS2 | P10T-E | Human | Esophagus | ESCC | 4.92e-13 | 1.19e-01 | 0.116 |
| 80351 | TNKS2 | P11T-E | Human | Esophagus | ESCC | 3.87e-07 | 4.13e-01 | 0.1426 |
| 80351 | TNKS2 | P12T-E | Human | Esophagus | ESCC | 1.11e-21 | 4.59e-01 | 0.1122 |
| 80351 | TNKS2 | P15T-E | Human | Esophagus | ESCC | 3.55e-20 | 5.02e-01 | 0.1149 |
| 80351 | TNKS2 | P16T-E | Human | Esophagus | ESCC | 2.06e-21 | 3.75e-01 | 0.1153 |
| 80351 | TNKS2 | P17T-E | Human | Esophagus | ESCC | 4.07e-07 | 2.43e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003220615 | Oral cavity | OSCC | positive regulation of telomere maintenance | 34/7305 | 52/18723 | 1.05e-04 | 7.81e-04 | 34 |
| GO:006082810 | Oral cavity | OSCC | regulation of canonical Wnt signaling pathway | 128/7305 | 253/18723 | 1.11e-04 | 8.16e-04 | 128 |
| GO:00322006 | Oral cavity | OSCC | telomere organization | 85/7305 | 159/18723 | 1.47e-04 | 1.04e-03 | 85 |
| GO:00322107 | Oral cavity | OSCC | regulation of telomere maintenance via telomerase | 34/7305 | 53/18723 | 1.84e-04 | 1.25e-03 | 34 |
| GO:006007010 | Oral cavity | OSCC | canonical Wnt signaling pathway | 148/7305 | 303/18723 | 2.89e-04 | 1.82e-03 | 148 |
| GO:190435610 | Oral cavity | OSCC | regulation of telomere maintenance via telomere lengthening | 37/7305 | 61/18723 | 5.02e-04 | 2.95e-03 | 37 |
| GO:00701986 | Oral cavity | OSCC | protein localization to chromosome, telomeric region | 20/7305 | 29/18723 | 1.05e-03 | 5.39e-03 | 20 |
| GO:00301779 | Oral cavity | OSCC | positive regulation of Wnt signaling pathway | 73/7305 | 140/18723 | 1.06e-03 | 5.46e-03 | 73 |
| GO:190435816 | Oral cavity | OSCC | positive regulation of telomere maintenance via telomere lengthening | 24/7305 | 37/18723 | 1.29e-03 | 6.44e-03 | 24 |
| GO:00322129 | Oral cavity | OSCC | positive regulation of telomere maintenance via telomerase | 22/7305 | 34/18723 | 2.14e-03 | 9.81e-03 | 22 |
| GO:00352646 | Oral cavity | OSCC | multicellular organism growth | 65/7305 | 132/18723 | 1.06e-02 | 3.60e-02 | 65 |
| GO:000020923 | Oral cavity | EOLP | protein polyubiquitination | 62/2218 | 236/18723 | 7.88e-10 | 5.90e-08 | 62 |
| GO:003304422 | Oral cavity | EOLP | regulation of chromosome organization | 50/2218 | 187/18723 | 1.80e-08 | 7.94e-07 | 50 |
| GO:001605523 | Oral cavity | EOLP | Wnt signaling pathway | 89/2218 | 444/18723 | 3.66e-07 | 1.06e-05 | 89 |
| GO:019873823 | Oral cavity | EOLP | cell-cell signaling by wnt | 89/2218 | 446/18723 | 4.49e-07 | 1.25e-05 | 89 |
| GO:005105222 | Oral cavity | EOLP | regulation of DNA metabolic process | 75/2218 | 359/18723 | 5.81e-07 | 1.53e-05 | 75 |
| GO:000072322 | Oral cavity | EOLP | telomere maintenance | 36/2218 | 131/18723 | 8.39e-07 | 2.10e-05 | 36 |
| GO:003011123 | Oral cavity | EOLP | regulation of Wnt signaling pathway | 67/2218 | 328/18723 | 5.11e-06 | 1.04e-04 | 67 |
| GO:009026323 | Oral cavity | EOLP | positive regulation of canonical Wnt signaling pathway | 29/2218 | 106/18723 | 1.04e-05 | 1.86e-04 | 29 |
| GO:003220422 | Oral cavity | EOLP | regulation of telomere maintenance | 24/2218 | 80/18723 | 1.09e-05 | 1.93e-04 | 24 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TNKS2 | SNV | Missense_Mutation | novel | c.2611G>T | p.Val871Phe | p.V871F | Q9H2K2 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| TNKS2 | SNV | Missense_Mutation | novel | c.536N>T | p.Asp179Val | p.D179V | Q9H2K2 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TNKS2 | SNV | Missense_Mutation | novel | c.1169N>A | p.Gly390Glu | p.G390E | Q9H2K2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A08P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| TNKS2 | SNV | Missense_Mutation | c.2342N>T | p.Pro781Leu | p.P781L | Q9H2K2 | protein_coding | deleterious(0) | possibly_damaging(0.687) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TNKS2 | SNV | Missense_Mutation | novel | c.3187N>A | p.Glu1063Lys | p.E1063K | Q9H2K2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| TNKS2 | SNV | Missense_Mutation | novel | c.2855N>T | p.Gly952Val | p.G952V | Q9H2K2 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| TNKS2 | SNV | Missense_Mutation | rs758437700 | c.2251G>A | p.Glu751Lys | p.E751K | Q9H2K2 | protein_coding | tolerated(0.06) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TNKS2 | SNV | Missense_Mutation | c.1225N>C | p.Glu409Gln | p.E409Q | Q9H2K2 | protein_coding | tolerated(0.11) | benign(0.038) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| TNKS2 | SNV | Missense_Mutation | c.265G>A | p.Asp89Asn | p.D89N | Q9H2K2 | protein_coding | tolerated(0.14) | probably_damaging(0.992) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| TNKS2 | insertion | Frame_Shift_Ins | novel | c.1377_1378insATGGAAGAATTGGGTTTCAGCTTATTAAGGATCTCAA | p.Asn460MetfsTer28 | p.N460Mfs*28 | Q9H2K2 | protein_coding | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 80351 | TNKS2 | DRUGGABLE GENOME, ENZYME | inhibitor | 404859121 | ||
| 80351 | TNKS2 | DRUGGABLE GENOME, ENZYME | inhibitor | 404859119 | ||
| 80351 | TNKS2 | DRUGGABLE GENOME, ENZYME | inhibitor | 404859123 | ||
| 80351 | TNKS2 | DRUGGABLE GENOME, ENZYME | PMID27841036-Compound-37 | |||
| 80351 | TNKS2 | DRUGGABLE GENOME, ENZYME | inhibitor | 404859118 | ||
| 80351 | TNKS2 | DRUGGABLE GENOME, ENZYME | inhibitor | 404859120 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |